美國斯克利普斯研究所2024年招聘博士后（疫苗開發(fā)）

斯克利普斯研究所（Scripps Research，舊稱The Scripps Research Institute，縮寫為TSRI）是一所私立的非營利性的生物醫(yī)學(xué)研究機構(gòu)，成立于1924年。斯克里普斯研究學(xué)院是美國同類機構(gòu)中最大的。斯克里普斯研究所基礎(chǔ)研究含蓋免疫學(xué)，分子和細(xì)胞生物學(xué)，化學(xué)，神經(jīng)科學(xué)，自身免疫性疾病，心血管病學(xué)，病毒學(xué)和合成疫苗的發(fā)展。TSRI在這些學(xué)科領(lǐng)域的研究均獲得國際上的公認(rèn)，其中以在生物分子的基本機構(gòu)和設(shè)計方式的研究方面表現(xiàn)尤為突出，是少數(shù)幾個世界領(lǐng)先的中心之一。根據(jù)美國新聞與世界報道在2007年進行的排名，斯克里普斯研究學(xué)院在美國最好的生物科學(xué)研究院中排名第7位，在最好的化學(xué)研究院中排名第6位。

Postdoctoral Associate – Zhu Lab

Employer

Scripps Research

Location

La Jolla, California

Salary

$70,000 to $80,000 + benefits

Closing date

Jul 29, 2024

Postdoctoral Positions Available

Postdoctoral positions are available in Dr. Jiang Zhu's laboratory for highly motivated candidates who are interested in vaccine development for viral pathogens such as HIV-1, HCV, Flu, SARS-CoV-1/2, MERS-CoV, Ebola/Marburg, RSV/hMPV, and ZIKV. Salary is in the range of $70,000 to $80,000 depending on prior experience and qualifications. Dr. Zhu holds a joint appointment in the Department of Integrative Structural and Computational Biology (ISCB) and the Department of Immunology and Microbiology at Scripps Research in La Jolla, CA (www.scripps.edu). Dr. Zhu's laboratory combines structure-based antigen design, protein nanoparticle engineering, animal immunization, single-cell technologies, and immunological assays to develop and evaluate next-generation vaccines. Multiple vaccine candidates are currently under clinical development with ongoing and planned phase-I human trials. Details of Dr. Zhu's laboratory, ongoing research projects, and recent publications can be found at www.jzhulab.org/

Dr. Zhu is also the co-founder of Uvax Bio LLC (www.uvaxbio.com), a vaccine biotechnology company that aims to address global health challenges with innovative vaccine solutions. An HIV-1 nanoparticle vaccine candidate developed by the Zhu lab is currently in the Phase 1 clinical trial in Australia (ANZCTR registration #: ACTRN12624000064505), which is sponsored by Uvax Bio. An NIH-sponsored Phase 1 clinical trial is under preparation and is expected to take place in early 2025.

Research projects will be focused on the development and validation of various microbial systems for expression of viral glycoproteins and nanoparticles, such as glycoengineered Escherichia coli, Pichia pastoris, and Saccharomyces cerevisiae. Microbially produced glycoprotein antigens will be structurally and functionally characterized to facilitate vaccine development.

Successful candidates will have a recent Ph.D. in microbiology, glycobiology, bioengineering, and other related fields. Candidates with knowledge and experience in bacterial and yeast expression, upstream and downstream processes, microbial fermentation in shake flasks and bioreactors, and subsequent harvesting and analyses are especially encouraged to apply. Plasmid construction and strain/clone generation may be required for this position. Extensive working experience in yeast systems will be a plus.

Interested applicants should send the following materials, preferably as a single PDF file, by email to Dr. Jiang Zhu (jiang@scripps.edu):

Cover letter indicating current and future research interests

Expected starting date

Curriculum vitae

Brief summary of previous research experience (2-3 pages)

Names and contact information for 3 references.

為防止簡歷投遞丟失請抄送一份至：boshijob@126.com（郵件標(biāo)題格式：應(yīng)聘職位名稱+姓名+學(xué)歷+專業(yè)+中國博士人才網(wǎng)）